Profile data is unavailable for this security.
About the company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
- Revenue in -- (TTM)--
- Net income in --
- Incorporated1966
- Employees--
- LocationRoche Holding AGGrenzacherstr. 124BASEL 4058SwitzerlandCHE
- Phone+41 9 732354295
- Websitehttp://www.roche.com
Mergers & acquisitions
| Acquired company | ROG:SWX since announced | Transaction value |
|---|---|---|
| Enterprise Therapeutics Ltd | -5.54% | 96.58m |
| Inflazome Ltd | -12.84% | 449.81m |
| Holder | Shares | % Held |
|---|---|---|
| APG Asset Management NVas of 30 Sep 2020 | 2.10m | 1.31% |
| Canada Pension Plan Investment Boardas of 31 Mar 2020 | 1.49m | 0.93% |
| Schroder Investment Management Ltd.as of 30 Jun 2020 | 777.39k | 0.49% |
| J.O. Hambro Capital Management Ltd.as of 31 Dec 2020 | 743.12k | 0.46% |
| Wellington Management Co. LLPas of 31 Dec 2020 | 654.54k | 0.41% |
| The Vanguard Group, Inc.as of 31 Jan 2021 | 643.58k | 0.40% |
| RBC Global Asset Management (UK) Ltd.as of 30 Jun 2020 | 591.68k | 0.37% |
| Credit Suisse Asset Management (Schweiz) AGas of 30 Jun 2020 | 484.79k | 0.30% |
| S.W. Mitchell Capital LLPas of 31 Mar 2020 | 464.57k | 0.29% |
| GQG Partners LLCas of 30 Jun 2020 | 457.59k | 0.29% |
